Does day-3 LH/FSH ratio influence in vitro fertilization outcome in PCOS patients undergoing controlled ovarian hyperstimulation with different GnRH-analogue

Gynecological Endocrinology

Volumn 28, Issue 6, 2012, Pages 422-424

  Orvieto, Raoul ^a   Meltcer, Simion ^a   Liberty, Gad ^a   Rabinson, Jacob ^a   Anteby, Eyal Y ^a   Nahum, Ravit ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Day 3 LH FSH ratio; GnRH agonist; GnRH antagonist; IVF outcome; PCOS; Pregnancy

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; FOLLITROPIN; GONADORELIN; LUTEINIZING HORMONE; PROGESTERONE; TRIPTORELIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EMBRYO TRANSFER; FEMALE; FERTILIZATION; FERTILIZATION IN VITRO; HUMAN; INFERTILITY THERAPY; OOCYTE; OVARIAN STIMULATION; OVARY POLYCYSTIC DISEASE; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL;

ADULT; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFERTILITY, FEMALE; LUTEINIZING HORMONE; MENSTRUAL CYCLE; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY RATE; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84861020794     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2011.633661     Document Type: Article

References (19)

1. Rotterdam ESHRE/ASRM- Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
2. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008;89:505-522.
3. Buyalos RP, Lee CT. Polycystic ovary syndrome: Pathophysiology and outcome with in vitro fertilization. Fertil Steril 1996;65:1-10. (Pubitemid 26006639)
4. Dor J, Shulman A, Levran D, Ben-Rafael Z, Rudak E, Mashiach S. The treatment of patients with polycystic ovarian syndrome by in vitro fertilization and embryo transfer: A comparison of results with those of patients with tubal infertility. Hum Reprod 1990;5:816-818. (Pubitemid 20357671)
5. Urman B, Fluker MR, Yuen BH, Fleige-Zahradka BG, Zouves CG, Moon YS. The outcome of in vitro fertilization and embryo transfer in women with polycystic ovary syndrome failing to conceive after ovulation induction with exogenous gonadotropins. Fertil Steril 1992;57:1269-1273.
6. Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM. GnRHantagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: A meta-analysis. Reprod Biomed Online 2006;13:628-638. (Pubitemid 44760885)
7. Damario MA, Barmat L, Liu HC, Davis OK, Rosenwaks Z. Dual suppression with oral contraceptives and gonadotrophin releasinghormone agonists improves in vitro fertilization outcome in high responder patients. Hum Reprod 1997;12:2359-2365. (Pubitemid 27522187)
8. Orvieto R, Meltcer S, Homburg R, Nahum R, Rabinson J, Ashkenazi J. What is the preferred GnRH analogue for polycystic ovary syndrome patients undergoing controlled ovarian hyperstimulation for in vitro fertilization? Fertil Steril 2009;91:1466-1468.
9. Orvieto R, Nahum R, Meltcer S, Homburg R, Rabinson J, Anteby EY, Ashkenazi J. Controlled ovarian hyperstimulation in polycystic ovary syndrome patients: The role of body mass index. RBM Online 2009;18:333-336
10. Insler V, Shoham Z, Barash A, Koistinen R, Seppälä M, Hen M, Lunenfeld B, Zadik Z. Polycystic ovaries in non-obese and obese patients: Possible pathophysiological mechanism based on new interpretation of facts and findings. Hum Reprod 1993;8:379-384. (Pubitemid 23106812)
11. Mulders AG, Laven JS, Eijkemans MJ, Hughes EG, Fauser BC. Patient predictors for outcome of gonadotrophin ovulation induction in women with normogonadotrophic anovulatory infertility: A metaanalysis. Hum Reprod Update 2003;9:429-449. (Pubitemid 37408176)
12. Pagán YL, Srouji SS, Jimenez Y, Emerson A, Gill S, Hall JE. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: Investigation of hypothalamic and pituitary contributions. J Clin Endocrinol Metab 2006;91: 1309-1316.
13. Shoham Z. The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertil Steril 2002;77:1170-1177. (Pubitemid 34626325)
14. Ashkenazi J, Farhi J, Orvieto R, Homburg R, Dekel A, Feldberg D, Ben Rafael Z. Polycystic ovary syndrome patients as oocyte donors: The effect of ovarian stimulation protocol on the implantation rate of the recipient. Fertil Steril 1995;64:564-567.
15. Taylor AE, McCourt B, Martin K, Anderson EJ, Adams J, Schoebfeld D, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with PCOS. J Clin Endocrinol Metab 1997;82:2248-56. (Pubitemid 27287593)
16. Gordon UD, Harrison RF, Fawzy M, Hennelly B, Gordon AC. Arandomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome. Fertil Steril 2001;75:324-331. (Pubitemid 32112109)
17. Mendoza C, Ruiz-Requena E, Ortega E, Cremades N, Martinez F, Bernabeu R, Greco E, Tesarik J. Follicular fluid markers of oocyte developmental potential. Hum Reprod 2002;17:1017-1022. (Pubitemid 34411139)
18. Clifford K, Rai R, Watson H, Franks S, Regan L. Does suppressing luteinising hormone secretion reduce the miscarriage rate? Results of arandomised controlled trial. BMJ 1996;312:1508-1511. (Pubitemid 26178256)
19. Orvieto R. Can we eliminate severe ovarian hyperstimulation syndrome? Hum Reprod 2005;20:320-322. (Pubitemid 40277597)